BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/30/2025 7:07:08 AM | Browse: 7 | Download: 21
 |
Received |
|
2025-05-30 02:03 |
|
Peer-Review Started |
|
2025-05-30 02:03 |
|
First Decision by Editorial Office Director |
|
2025-06-06 03:42 |
|
Return for Revision |
|
2025-06-06 03:42 |
|
Revised |
|
2025-06-15 01:17 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-01 02:47 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-01 07:29 |
|
Articles in Press |
|
2025-09-01 07:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-24 00:39 |
|
Publish the Manuscript Online |
|
2025-10-30 07:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Role of anti-inflammatory agent colchicine in atherosclerotic cardiovascular disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kevan English and Christine Uwibambe |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kevan English, MD, Department of Internal Medicine, University of Nebraska Medical Center, S 42nd & Emile St, Omaha, NE 68198, United States. keenglish@unmc.edu |
| Key Words |
Colchicine; Coronary artery disease; Atherosclerosis; Inflammation; Myocardial infarction; C-reactive protein; Cardiovascular disease |
| Core Tip |
Inflammation is now recognized as an essential component of atherosclerosis, and the anti-inflammatory agent colchicine, through a variety of actions, suppresses this response. Results from a meta-analysis of several randomized controlled trials that evaluated colchicine’s efficacy on cardiovascular outcomes led to its recent approval by the United States Food and Drug Administration for the management and prevention of atherosclerotic cardiovascular disease. It has been shown to reduce the risk of recurrent major adverse cardiovascular events, and clinical data now supports its use for secondary prevention in patients with established coronary artery disease, presumably due to its anti-inflammatory properties. |
| Publish Date |
2025-10-30 07:07 |
| Citation |
English K, Uwibambe C. Role of anti-inflammatory agent colchicine in atherosclerotic cardiovascular disease. World J Clin Cases 2025; 13(31): 110123 |
| URL |
https://www.wjgnet.com/2307-8960/full/v13/i31/110123.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v13.i31.110123 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
